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Abstract
Cigarette smoke (CS) is the major cause of chronic obstructive pulmonary disease (COPD). Interleukin-17A (IL-17A)
is a pivotal cytokine that regulates lung immunity and inflammation. The aim of the present study was to investigate
how IL-17A regulates CS-induced lung inflammation in vivo. IL-17A knockout (KO) mice and neutralization of IL-17A
in wild-type (WT) mice reduced macrophage and neutrophil recruitment and chemokine (C-C motif) ligand 2 (CCL2),
CCL3 and matrix metalloproteinase (MMP)-12 mRNA expression in response to acute CS exposure. IL-17A
expression was increased in non-obese diabetic (NOD) severe combined immunodeficiency SCID) mice with
non-functional B- and T-cells over a 4-week CS exposure period, where macrophages accumulated to the same
extent as in WT mice. Gene expression analysis by QPCR (quantitative real-time PCR) of isolated immune cell
subsets detected increased levels of IL-17A transcript in macrophages, neutrophils and NK/NKT cells in the lungs
of CS-exposed mice. In order to further explore the relative contribution of innate immune cellular sources,
intracellular IL-17A staining was performed. In the present study, we demonstrate that CS exposure primes natural
killer (NK), natural killer T (NKT) and γ δ T-cells to produce more IL-17A protein and CS alone increased the
frequency of IL17+ γ δ T-cells in the lung, whereas IL-17A protein was not detected in macrophages and neutrophils.
Our data suggest that activation of innate cellular sources of IL-17A is an essential mediator of macrophage
accumulation in CS-exposed lungs. Targeting non-conventional T-cell sources of IL-17A may offer an alternative
strategy to reduce pathogenic macrophages in COPD.
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INTRODUCTION
Cigarette smoke (CS) is the major cause of chronic obstructive
pulmonary disease (COPD) and accounts for ∼85% of cases
in industrialized countries, but other environmental pollutants,
especially biomass fuel smoke, are important causes in devel-
oping countries [1]. CS causes lung inflammation where mac-
rophages and neutrophils are prominent, leading to oxidative
stress, emphysema, small airways fibrosis, mucus hypersecretion
and progressive airflow limitation [1]. Both neutrophils and mac-
rophage lineage cells are essential effectors in these processes.
Abbreviations: Ab, antibody; APC, allophycocyanin; BALF, bronchoalveolar lavage fluid; CCL, C-C (motif) chemokine ligand; COPD, chronic obstructive pulmonary disease; CS, cigarette
smoke; DMEM, Dulbecco’s modified Eagle’s medium; IL, interleukin; IL-17R, IL-17 receptor; KO, knockout; mAb, monoclonal antibody; MMP, matrix metalloproteinase; NK, natural killer;
PE, phycoerythrin; QPCR, quantitative real-time PCR; TGF, transforming growth factor; Th17, T helper 17 cell; WT, wild-type.
Correspondence: Dr Ross Vlahos (email ross.vlahos@rmit.edu.au).
However, this myelo-monocytic inflammatory response to CS re-
sponds poorly to current anti-inflammatory treatments, such as
glucocorticosteroids and there is intense research to identifymore
effective treatments for CS-induced lung damage, particularly in
the early stages of the disease before the onset of intractable em-
physema. Smoke exposure is also directly implicated in neutro-
phil variant asthma, ACOS (asthma–COPD overlap syndrome),
interstitial lung disease, rheumatic lung disease and infectious
exacerbations of these conditions.
Interleukin (IL)-17A is increasingly recognized as a fun-
damentally important regulator of cellular immunity and is
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conventionally considered to arise predominantly from the ‘Th17’
(T helper 17 cells)-specific subset of Th cells (CD4 cells), which
is phenotypically and functionally distinct from Th-1 and Th-2
cells and from T regulatory (Treg) cells [2]. Now identified in
both rodents and humans, in mice the initial polarization of naive
Th cells towards the Th17 subtype depends on T-cell receptor sig-
nalling and the presence of transforming growth factor (TGF)-β
and IL-6 [3,4]. Human Th17 cells also display similarities with
mouse Th17 cells as IL-1β, IL-6 or IL-23 drive the differentiation
of naive Th cells towards the Th17 subtype, whereas the data on
the role of TGF-β are controversial [5,6].
Most current evidence supports IL-17A as having an import-
ant role as a pro-inflammatory cytokine uniquely positioned at the
interface of innate and adaptive immunity [7]. IL-17A induces
the release of secondary pro-inflammatory chemokines and
growth factors in most epithelial and mesenchymal cells lead-
ing, in turn, to the recruitment and accumulation of neutro-
phils [8]. Specifically, it is known that IL-17A stimulates the
production of C-X-C chemokines (such as chemokine (C-X-
C motif) ligand 8, CXCL8), granulocyte-chemotactic protein-2
and growth-stimulatory cytokines such as granulocyte colony-
stimulating factor (G-CSF) and granulocyte/macrophage colony-
stimulating factor (GM-CSF) [9,10]. IL-17A, in particular, pro-
motes neutrophil activity locally in inflamed tissues as judged
by increased activity of myeloperoxidase, neutrophil elastase and
matrix metalloproteinase (MMP)-9 after local administration of
recombinant IL-17 protein [11,12].
It is now becoming apparent that cell types other than Th17
can also produce IL-17A. Studies with human cells indicate that
CD8 cells and γ δ T-cells can be sources of IL-17A [13]. The same
is true in mice in which invariant natural killer T-cells, Paneth
cells and even granulocytes can produce IL-17A [14]. In contrast
with the restricted expression of IL-17A, the IL-17 receptor (IL-
17R) is ubiquitously expressed; hence, this pathway canmodulate
many cell/tissue types. A pathogenic role for IL-17A has been
postulated in disorderswheremonocyte lineages are implicated as
important effector cells [15,16]. There are now studies exploring
the effects of IL-17A on monocytes, macrophages, osteoclasts
and dendritic cells (DCs), where IL-17A regulated monocyte-
derived cytokines [17,18].
IL-17A has also been implicated in lung diseases including
asthma. IL-17A promotes recruitment and survival of airway
macrophages during allergen-induced airway inflammation [19].
IL-17A is increased in asthmaticBALF, sputumand blood [20,21]
and increased immunoreactivity for IL-17A in the asthmatic air-
way submucosa is associated with impaired lung function [21]. In
IL-17A knockout (KO) mice, the allergen-induced airway hyper-
reactivity to methacholine is significantly reduced [22]. Systemic
blockade of IL-17A also inhibited the allergen-induced accumu-
lation of neutrophils in the airway [23]. Moreover, IL-17A levels
correlate with neutrophil counts in the sputum of moderate to
severe asthmatics [24].
There is also evidence for an emerging role for IL-17A
in COPD. IL-17A+ cells increased in bronchial submucosa of
chronic smokers and stable COPD subjects [25,26]. Of interest is
that patients with COPD have an increased number of NKT cells
in the blood, lungs and sputum [27–29] and that NKT cells are a
source of IL-17A [30]. Mechanistic studies in experimental CS
models also demonstrate that genetic ablation of the IL-17R pre-
ventedmice against the development of emphysema [31]. Studies
have also demonstrated that neutrophilic inflammation induced
byCS exposure is potently suppressed inmice deficient in IL-17A
[32] and in response to neutralization with a blocking antibody
(Ab) [33].
Given that the interplay of innate immune sources of IL-17A
and macrophages is poorly understood we have investigated their
potential roles. In the present study, we demonstrate that IL-17A
is not only required for CS-mediated macrophage accumulation
but also that this process occurs in the absence of functional B-
and T-cells, implicating alternative cellular sources of IL-17A in
response to CS.
MATERIALS AND METHODS
Animals
Specific pathogen-free WT (wild-type; C57BL/6) or IL-17A de-
ficient (IL-17A−/−) mice aged 7–10 weeks and weighing ∼20 g
were obtained from Hudson Institute of Medical Research. Spe-
cific pathogen-free BALB/c mice (aged 7 weeks) were obtained
from the Animal Resource Centre Pty. Ltd. and NOD SCID mice
(NOD.CB17-Prkdcscid, aged 7 weeks) were obtained from Mon-
ash Animal Services. The animals were housed at 20 ◦C on a
12-h light/12-h dark cycle in sterile micro-isolators and fed on
a standard sterile diet of Purina mouse chow with water allowed
ad libitum. The experiments described in the present paper were
approved by the Animal Ethics Committee of The University of
Melbourne and conducted in compliance with the guidelines of
the National Health and Medical Research Council of Australia
on animal experimentation.
Cigarette smoke exposure
Mice were placed in an 18 litre perspex chamber in a class II
biosafety cabinet and exposed to CS generated from nine ci-
garettes per day for 4 days, as previously described [34]. The
mean total suspended particulatemass concentration in the cham-
ber containing CS was approximately 420 mg/m3. Commercially
available filter-tipped cigarettes (manufactured by Philip Morris)
of the following composition were used: 16 mg or less of tar,
1.2 mg or less of nicotine and 15 mg or less of CO. In some
experiments, mice were exposed to CS for 2 and 4 weeks. Sham-
exposed mice were placed in an 18 litre perspex chamber but
did not receive CS. On the fifth day, mice were killed by an in-
traperitoneal (ip) injection of sodium pentobarbitone (360 mg/kg,
Sigma–Aldrich) and the lungs were lavaged with PBS. Group
sizes of eight to 12 mice per treatment were used.
Bronchoalveolar lavage
Lungs from each terminally anaesthetized mouse were lavaged
in situ with a 400 μl aliquot of PBS, followed by three 300 μl
aliquots of PBS as previously described [34]. The total number
of viable cells in the bronchoalveolar lavage fluid (BALF) was
determined, cytospins were prepared and cells were differentiated
by standard morphological criteria. Whole lungs were cleared of
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blood via right ventricular perfusion of the heart with 5 ml of
PBS, rapidly excised en bloc, snap-frozen in liquid nitrogen and
stored at −80 ◦C until required.
Quantitative real-time PCR (QPCR)
Total RNAwas extracted from 15 mg of whole lung tissue pooled
from five to eight mice per treatment group using RNeasy Mini
Kits (Qiagen), and reverse transcription with High Capacity
RNA-to-cDNA Kit (Life Technologies) and triplicate real-time
PCRs with Life Technologies pre-developed Taqman assay re-
agents and 18S rRNA internal control were done as previously
described [34].
Intranasal administration of anti-IL-17A monoclonal
antibody
Mice were anaesthetized lightly by inhalation of methoxy-
flurane vapour and 50 μl of PBS containing isotype control
[rat anti-mouse IgG2a monoclonal Ab (mAb), 50 μg/mouse,
R&D Systems] or anti-IL-17A mAb (rat anti-mouse IgG2a,
50 μg/mouse, R&D Systems) administered intranasally 1 h be-
fore the first CS exposure on days 1–4 of the experimental
protocol.
Preparation of lung single-cell suspensions,
antibodies and flow cytometry
Single-cell suspensionwas prepared as previously described [35].
Briefly, lungs were minced with scissors and incubated with PBS
containing Liberase (Roche) for 45 min at 37 ◦C in a shaking
incubator. Cells were then washed with FACS buffer (PBS con-
taining 2% FBS) and harvested by centrifugation (400 g at 4 ◦C
for 10 min) and red blood cells lysed in red blood cell lysis buf-
fer (1.55 M NH4Cl, 0.1 M KHCO3 and 10 mM disodium EDTA,
pH 7.4) for 5 min at room temperature. Cellswere filtered through
a 40 μm pore-size nylon net strainer, washed and resuspended in
Dulbecco’s modified Eagle’s medium (DMEM) containing 2.5%
FBS prior to surface staining. Cell counts were carried out using
ethidium bromide/Acridine Orange exclusion.
To avoid non-specific binding of Abs to FcRγ ((fragment,
crystallizable) receptor gamma), FACS buffer containing anti-
mouse CD16/32 mAb (Mouse BD Fc BlockTM; 2.4G2, BD Bios-
ciences) was added to all primary stains. All Abs were pur-
chased fromBDBiosciences unless otherwise stated. Anti-mouse
Abs FITC-conjugated CD45 (eBisocience), γ δ-T cell receptor
(TCR) (eBioscience), phycoerythrin (PE)-conjugated CD49b,
epithelial cell adhesion molecule (EpCAM) (eBioscience), ma-
jor histocompatibility complex class II (MHCII) (Mouse I-A[d]),
allophycocyanin (APC)-conjugated CD3, CD14 (eBioscience),
cluster of differentiation 4 (CD4) (eBioscience), CD11b, TCRβ,
PE-CyTM7-conjugated CD11c (eBioscience), CD19 and Pacific
Blue-conjugated CD4, F4/80 (eBioscience), APC-CyTM7 con-
jugated CD8, APC-eFluor 780 conjugated Ly-6G (Gr-1, eBios-
cience). A strict gating strategy was used to determine different
immune cell populations as previously described [35]. Briefly,
for all cell sorting, cells were gated to exclude doublets and non-
viable cells (either by propidium iodide, PI or byDAPI exclusion).
Lymphocytes were gated according to size andCD4+ T-cells were
sorted as CD4+, CD11c−, Ly6G− and CD49b−. NK/NKT cells
Figure 1 Effect of CS exposure on BALF cellularity in WT and
IL-17A-/- mice
IL-17A−/− mice have reduced BALF total cell number (A), macrophages
(B) and neutrophils (C) in response to 4 days of CS exposure. Data are
shown as means +− S.E.M. for eight to 12 mice per treatment group.
White bars represent sham-exposed mice and black bars represent
smoke-exposed mice. *P< 0.001 compared with corresponding sham,
†P< 0.001 compared with WT smoke.
were sorted as CD49b+, CD4−, CD11c− and Ly6G−. Myeloid
cells were further gated as large granular cells and macrophages
(including DCs) sorted as CD11c+, Ly6G−, CD4− and CD49b−.
Neutrophils were gated and sorted as Ly6G+, CD4−, CD11c−
and CD49b−. Cells were sorted on the Aria Cell Sorter (BD
Biosciences). Flowjo software (Treestar) was used to analyse
data.
Intracellular flow cytometry
In addition to the gating strategy above, CD49b and TCRβ ex-
pression was used to further differentiate natural killer (NK)
and natural killer T (NKT) cells for intracellular IL-17A stain-
ing. γ δ T-cells were also gated using γ δ-TCR and CD3+ mark-
ers. A total of 1× 107 single cells from the lungs of mice ex-
posed to CS or sham/air for 4 days were cultured in a 24-well
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Figure 2 Effect of 4 days of CS exposure on whole lung gene expression in WT and IL-17A−/− mice
mRNA expression for all genes was measured simultaneously under identical conditions using QPCR. Responses are
shown as fold expression relative to 18S rRNA. Data are shown as means +− S.E.M. of three replicates, as previously
described [34]. White bars represent sham-exposed mice and black bars represent CS-exposed mice.
plate in DMEM containing 2.5% FBS and 10 mg/ml brefeldin
A (eBioscience) with/without 50 ng/ml PMA and 1 μg/ml iono-
mycin for 4 h at 37 ◦C in 5% CO2. Cells were washed twice
in ice-cold PBS and harvested by centrifugation (400 g at 4 ◦C
for 10 min) before surface staining for each of the cell sub-
sets. The following anti-mouse primary Abs were used to sur-
face stain cell subsets; FITC-conjugated CD45 (Biolegend), γ δ-
TCR (eBioscience), PE-conjugated CD45 (Biolegend), γ δ-TCR
(eBioscience), CD49b (BD Biosciences), APC-conjugated CD3
(BDBiosciences), CD4 (eBioscience), CD11b, TCRβ (BDBios-
ciences), PE-CyTM7-congugated CD11c, CD45 (eBioscience)
and Pacific Blue-conjugated CD4 (BD Biosciences), F4/80 (Bio-
legend), APC-CyTM7 conjugated CD8, Ly-6G (Gr-1, eBios-
cience). Cells were stained for 30 min at 4 ◦C and non-specific
binding prevented using anti-mouse CD16/32 mAb (Mouse BD
Fc BlockTM; 2.4G2). After Ab incubation, cells were washed
twice and resuspended in FACS buffer. Intracellular staining was
carried out using the Fixation and Permeabilization Kit (eBios-
cience) according to the manufacturer’s instructions. IL-17A was
stained using anti-mouse PE-CyTM-7-conjugated (eBioscience)
or PE-conjugated IL-17A (BD Biosciences). Cells were analysed
using the LSR Fortessa (BD Biosciences) and for all cell subsets
doublets were excluded by forward/side scatter width compared
with height and side scatter-width compared with height and only
CD45+ events included in the analysis. Flowjo software (Tree-
star) was used to analyse data.
Statistical analyses
As data were normally distributed, they are presented as grouped
data expressed as means+−S.E.M.; n represents the number of
mice. Differenceswere determined by one-wayANOVA followed
by Bonferroni post-hoc test for multiple comparisons, where ap-
propriate. All statistical analyseswere performed usingGraphPad
PrismTM for Windows (version 5.03). Probability levels less than
0.05 (P< 0.05) were taken to indicate statistical significance.
RESULTS
Deletion of IL-17A inhibits CS-induced BALF
cellularity and expression of
monocyte/macrophage chemokines
In WT C57BL/6 mice exposed to CS generated from nine ci-
garettes per day for 4 days, there was a significant increase
in the total number of cells (4.62+− 0.29× 105), neutrophils
(4.10+− 0.33× 104) and macrophages (4.20+− 0.29× 105) in
BALF (Figures 1A–1C) compared with sham-exposed mice
(1.25+− 0.20× 105, 0.02+− 0.010× 104 and 1.24+− 0.20× 105
respectively; P< 0.05). However, IL-17A−/− mice ex-
posed to CS for 4 days had significantly fewer total
cells (2.12+− 0.17× 105), neutrophils (0.060+− 0.01× 104)
and macrophages (2.12+− 0.17× 105) compared with CS-
exposed WT mice (Figures 1A–1C; P< 0.05). Total cell
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(1.48+− 0.12× 105), neutrophil (0.03+− 0.02× 104) and macro-
phage (1.47+− 0.12× 105) numbers in sham-exposed IL-17A−/−
mice were similar to those in sham-exposed WT mice (Fig-
ures 1A–1C).WTmice treated with CS hadmore IL-17A, CCL2,
CCL3 and MMP-12 as measured by QPCR in whole lung com-
pared with sham-exposed WT mice (Figure 2). However, IL-
17A−/− mice had markedly reduced levels of IL-17A, CCL2,
CCL3 and MMP-12.
Anti-IL-17A antibody blocks CS-induced BALF
phagocytic leucocyte accumulation and expression
of monocyte/macrophage chemokines
In CS-exposed (4 days) BALB/c mice treated with isotype con-
trol Ab, there was a significant increase in the total num-
ber of cells (7.27+− 0.27× 105), neutrophils (1.99+− 0.24× 105)
and macrophages (5.250+− 0.33× 105) in BALF compared
with sham-exposed isotype-treated mice (2.96+− 0.23× 105,
0.08+− 0.03× 105 and 2.88+− 0.22× 105 respectively; Fig-
ures 3A–3C; P< 0.05). However, CS-exposed mice treated with
an anti-IL-17A (50 μg/mouse) mAb had significantly reduced
total cells (2.99+− 0.19× 105), neutrophils (0.48+− 0.13× 105)
and macrophages (2.50+− 0.15× 105) compared with isotype-
treated CS-exposed mice (Figures 3A–3C; P< 0.05). Anti-IL-
17A mAb had no effect on baseline total, neutrophil and macro-
phage cell numbers in sham-exposed animals (Figures 3A–3C).
CS-exposed animals had markedly elevated mRNA levels of IL-
17A, the chemokinesCCL2 andCCL3, and the proteaseMMP-12
(Figures 4A–4D). Anti-IL-17 mAb (50 μg/mouse) alone had no
effect on baseline mRNA levels of IL-17A, CCL2, CCL3 and
MMP-12, but reduced CS-induced increases in these gene tran-
scripts (Figures 4A–4D).
Cigarette smoke induces IL-17A expression in the
lungs of mice lacking functional T- and B-cells
NOD SCID mice were exposed to CS for 4 days, 2 weeks and
4 weeks. Over this 4-week CS exposure period, an increased pre-
valence of the foamy activated BALFmacrophage phenotypewas
observed and neutrophilic inflammation becamemore prominent,
as assessed by staining differential cytospots (Figure 5A). With
increasing length of CS exposure, there was a progressive in-
crease in IL-17A gene expression in the lungs of NODSCIDmice
(Figure 5B). Total BALF macrophage numbers were determined
in BALB/c mice and NOD SCID mice, where accumulation of
macrophages in response to CS exposure was maintained in the
absence of functional T- and B-cells (Figure 5C). Neutrophilic
inflammation significantly progressed with increasing length of
CS exposure in both BALB/c and NOD SCID mice; however,
peak neutrophil numbers were reduced by approximately 2-fold
in NOD SCID mice (Figure 5D).
Alternative innate cellular sources of IL-17A in CS-
exposed lungs
The capacity to respond to CS challenge in NOD SCID mice
implicates alternative additional sources of IL-17A. To invest-
igate these further, cell populations were sorted from the lungs
of sham- and CS-exposed (4 days) BALB/c mice including mac-
rophages, neutrophils, NK/NKT cells and CD4+ T-cells. Given
Figure 3 Effect of anti-IL-17A mAb on BALF cellularity in CS-
exposed mice
Anti-IL-17A mAb inhibits CS (4 days)-induced increases in BALF total
cell number (A), macrophages (B) and neutrophils (C) in BALB/c mice.
Data are shown as means +− S.E.M. for eight mice per treatment group.
White bars represent isotype control-treated mice and black bars rep-
resent anti-IL-17A mAb (50 μg/mouse)-treated mice. *P< 0.001 com-
pared with respective sham, †P< 0.001 compared with isotype-treated
CS-exposed mice.
that γ δ T-cells in the lung mucosa are relatively infrequent, the
number of γ δ T-cells isolated from lungs was insufficient for
detection of IL-17A by QPCR. The levels of IL-17A transcripts
were subsequently determined in these isolated cell populations
by QPCR. Using this approach, detectable IL-17A gene expres-
sion was observed in macrophages (Figure 6A) and neutrophils
(Figure 6B), whereas IL-17A mRNA levels in phagocytic leuco-
cytes isolated from control sham-exposed lung were below the
limit of detection (Figures 6A–6B). Basal levels of IL-17A were
detected in NK/NKT cells isolated from control lungs and this
level increased 6-fold in NK/NKT cells sorted from CS-exposed
lungs (Figure 6C). IL-17A transcript was also detected in CD4+
T-cells, but did not increase in expression in response to CS ex-
posure (Figure 6D).
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Figure 4 Effect of anti-IL-17A mAb on whole lung gene expression in CS-exposed mice
Anti-IL-17A mAb inhibits CS (4 days)-induced increases in BALB/c whole lung IL-17A (A), CCL2 (B), CCL3 (C) and MMP-12
(D) mRNA. mRNA expression for all genes was measured simultaneously under identical conditions using QPCR. Re-
sponses are shown as fold expression relative to 18S rRNA. Data are shown as means +− S.E.M. of three replicates, as
previously described [34]. White bars represent isotype control-treated mice and black bars represent anti-IL-17A mAb
(50 μg/mouse)-treated mice.
To complement the QPCR experiments, intracellular IL-
17A staining was performed on individually sorted immune
cell populations. First, the frequency of NK, NKT and γ δ T-
cells was determined relative to all CD45+ lymphocytes in the
lung of sham- and CS-exposed mice. Using CD49b and TCRβ
expression to gate and differentiate NK and NKT cells, we show
that acute CS exposure does not increase the frequency of these
cells (Figure 7A). Indeed, a decrease in viable NK cells in lungs
of CS-exposed mice (2.1+− 0.3× 106) compared with sham mice
(3.4+− 0.14× 106) was observed (P< 0.05). Likewise gating for
γ δ T-cells using the γ δ-TCR and CD3 marker demonstrated no
increase in frequency of this cell type in the lung in response
to CS exposure (Figure 7B). We next investigated intracellular
IL-17A staining and found that the majority of cells positive
for intracellular IL-17A were innate immune cells (that included
NK, NKT and γ δ T-cells), whereas conventional CD4+ T-cells
represented a minor positive population (Figure 7C).
We initially analysed several different known sources of IL-
17A protein, but found that IL-17A staining was only consist-
ently and robustly detected primarily in NK, NKT and γ δ T-cells
with no detectable levels in macrophages and neutrophils. In
the present study, we demonstrate that 4 days of CS exposure
significantly primed the release of IL-17A protein expression.
Re-stimulation with PMA/ionomycin did not increase intracel-
lular IL-17A staining in NK and NKT cells from sham-exposed
mice. In contrast, the frequency of IL-17A+ NK and NKT cells
from re-stimulated CS exposed lungs increased ∼4- and 2-fold
respectively relative to sham (Figures 8A–8D). The frequency of
IL-17A+ γ δ T-cells relative to total γ δ T-cells increased in lungs
from 3% in sham to 17% in CS-exposed mice. Re-stimulation
with PMA/ionomycin activated 50% of the γ δ T-cells to pro-
duce IL-17A (Figure 8E). CS exposure also primed the release
of IL-17A as the percentage of IL-17A+ lung γ δ T-cells relative
to CD45+ cells increased 2-fold in CS-exposed mice following
re-stimulation (Figure 8F).
DISCUSSION
The present study has shown that activation of innate cellular
sources of IL-17A is an essential mediator of macrophage ac-
cumulation in CS-exposed lungs. Thus, targeting innate cellular
sources of IL-17A may offer an alternative strategy to reduce
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Figure 5 Effect of CS exposure on NOD SCID mouse BALF cellularity
NOD SCID mice were exposed to CS for 4 days, 2 weeks and 4 weeks. Sham mice were not exposed to CS. DiffQuik-stained
cytospins were generated from BAL cells isolated from NOD SCID (SCID) mice (A). IL-17A expression was measured using
QPCR in NOD SCID mice at the specified time points over the 4-week CS-exposure period (B). The total number of BAL
macrophages (C) and neutrophils (D) presented as means +− S.E.M. (n= 8–10). ††P< 0.01, ‡P< 0.001 compared with
sham; ***P< 0.001 compared with BALB/c mice.
pathogenic macrophages in COPD. IL-17A is a central regulator
of neutrophilic inflammation during infection of the airways [36]
and there is increasing evidence for its role in chronic lung dis-
eases including asthma, COPD and cystic fibrosis. In the healthy
setting, there are few IL-17A+ cells in the lung; however, there is
evidence for their accumulation in the airway mucosa in chronic
inflammatory conditions, such as COPD [25,26]. The emergence
of IL-17A+ cells appears to be associated with disease progres-
sion as IL-17A+ cells are present in chronic smokers [25,26] and
CS itself has been shown to be a potent inducer of Th17 cells
[31]. In our model, an increase in IL-17A expression within the
lung tissuewas observedwithin 1 week of CS exposure and levels
continued to increase over a 4-week exposure period. The persist-
ence of IL-17A+ cells within the airway mucosa of people with
chronic lung disease may not only sustain inflammation, but may
also alter essential host defence to respiratory infections, leading
to excessive inflammatory responses during exacerbations.
Amechanistic role for the IL-17 family has been characterized
using IL-17R-deficient mice, which did not develop emphysema
and did not accumulate macrophages in response to chronic
smoke exposure [31]. In this study, the authors also showed that
CS extract enhanced Th17 polarization of naive CD4+ and CD8+
T-cells [31]. Consistent with these findings, mRNA expression of
IL-17A has been observed in CD4+ and CD8+ T-cells within
the mucosa of tissue sections from COPD subjects [37,38]. In
addition to the classic Th17 paradigm, the findings presented
in the present study demonstrate that innate cellular sources of
IL-17A can compensate for non-functional adaptive immunity.
Here, NOD SCID mice, which are deficient in functional B-
and T-cells, expressed increasing levels of IL-17A transcript in
response to CS exposure over 4 weeks. Moreover, BALF macro-
phages also doubled in CS-exposed NOD SCID mice, which is
equivalent to that observed in WT mice with functional B- and
T-cells. Neutrophilic inflammation significantly progressed with
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Figure 6 Alternative innate cellular sources of IL-17A in CS-
exposed lungs
Individual immune cell populations were isolated from whole lung ho-
mogenates from sham- and CS (4 days)-exposed mice as detailed in
the Materials and methods section. Gene expression was determined
by QPCR analysis using an IL-17A Taqman assay in sorted macro-
phages/DCs (A), neutrophils (B), NK/NKT cells (C) and lymphocytes
(D). For analysis of macrophage/DC and neutrophil expression, CT
(IL-17A–18S CT) values are presented as IL-17A expression was not de-
tected (n.d.) in sham-exposed mice. For expression in CD4+ T-cells and
NK cells, the CT method was used as IL-17A transcript expression
was detected in sham-exposed mice.
increasing length of CS exposure in bothBALB/c andNODSCID
mice; however’ peak neutrophil numbers were reduced approx-
imately 2-fold in NOD SCID mice, suggesting that conventional
T-cells play an important role in the recruitment of neutrophils.
In addition, NOD SCID mice continue to develop pulmonary
emphysema when chronically exposed to CS as evidenced by
an increase in mean linear intercept and destructive index [39],
which implicates innate immune responses in pathological re-
modelling in COPD.
There is clinical evidence for alternative non-T cells sources of
IL-17A in COPD including the identification of IL-17A+ mac-
rophages and neutrophils present in the sub mucosal layer in
COPD lung tissue [40]. Consistent with this finding, increased
expression of IL-17A mRNA transcript was detected in both
macrophages and neutrophils in our study. This finding may be
particularly relevant to steroid-resistant inflammation, as neutro-
phils increase with disease severity despite escalating use of in-
Figure 7 Effect of short-term CS exposure on NK, NKT and γ δT-cell
frequency in the lungs
Lungs were harvested from mice following exposure to CS or
sham for 4 days. Representative dot plots gating on (A) lung NK
(CD49b+, TCRβ−) and NKT (CD49b+, TCRβ+) cells and (B) γ δ
T-(γ δ-TCR+, CD3+) cells. Numbers represent the frequency of each cell
population relative to single CD45+ lymphocytic events. (C) Single-
cell suspensions from CS-exposed mice were cultured for 4 h in me-
dium containing brefeldin with or without PMA/ionomycin and stained
for intracellular IL-17A. The frequency (percentage of total IL-17A+ cells)
of IL-17+ innate T-cells in innate immune cellular sources (that include
NK, NKT and γ δ T-cells) is compared with IL-17A+ conventional CD4+
T-cells.
haled glucocorticoids [41]. Macrophages also develop resistance
to steroids through loss of histone deacetylase 2 (HDAC2) ex-
pression in COPD [42]; hence, leucocytes may self-sustain innate
inflammation through IL-17A-dependent mechanisms. Neutro-
phils and macrophages have also been described as an important
source of IL-17A in infection-induced allergic airways disease
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Figure 8 The frequency of intracellular IL-17A+ innate T-cell subsets following CS exposure
Lungs were harvested from mice exposed to CS or sham for 4 days; single-cell suspensions were generated and cultured for
4 h in medium containing brefeldin with or without PMA/ionomycin prior to staining for intracellular IL-17A. Representative
dot plots gating on IL-17A+ cells in (A) lung NK, (C) NKT cells and (E) γ δ T-cells. Numbers represent the percentage of
IL-17+ cells relative to each cell subset. The adjacent histograms show the frequency of IL-17A+ NK (B), NKT (D) and γ δ T-
cells (F) relative to all single CD45+ cells. Pooled data from n= 4 mice per group. *P< 0.05, as determined by two-way
ANOVA.
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[43]. In the present study, NK/NKT cells isolated from the lungs
of CS-exposed mice also expressed IL-17A transcript.
We also evaluated IL-17A protein expression by intracellular
staining using flow cytometry. Much of the focus to date has been
on characterizing conventional T-cell sources of IL-17A in COPD
and CS exposure models as the relative low frequency of mucosal
innate cell populations has traditionally made it difficult to detect
expression in these cells. Unlike mRNA transcript levels, intra-
cellular detection of IL-17A in macrophages and neutrophils fell
below the detection limit of this assay, to suggest that these cell
types represent a minor contributor to IL-17A protein expression
in this setting. In the present study, we demonstrate that in re-
sponse to acute CS exposure, innate immune cells including NK,
NKT and γ δ T-cells become primed to release IL-17A and are
the predominant source of IL-17A relative to conventional CD4+
T-cells. The role of NK cells has not been extensively character-
ized in COPD; however, in a chronic CS challenge model, NK
cells were more primed to release inflammatory mediators in-
cluding IL-12 and IL-18 [44]. The primed state of NK cells in
response to CS may contribute to elevated IL-17A, as seen in our
study. The NK cell group 2D (NKG2D) ligand is also elevated
in CS-exposed pulmonary epithelial cells, which can sustain ac-
tivation of cytotoxic T-cells and NK cells [45]. Importantly, we
have recently demonstrated the persistence of NK/NKT cells and
IL-17A expression in the lungs of mice chronically exposed to
CS that included a 3-month cessation arm [46]. In the present
study, we now formally identify NK and NKT cells as an im-
portant cellular source of IL-17A in response to CS exposure.
In addition, we show that the frequency of IL-17A+ γ δ T-cells
increases even in the absence of re-stimulation. The evaluation
of γ δ T-cells in COPD has been difficult as this mucosal T-cell
population is relatively rare; however, it is known that in response
to respiratory infection such as Streptococcus pneumoniae, γ δ T-
cells can become a major source of IL-17A [47]. We believe that
further assessment of γ δ T-cell biology in COPD is needed in
order to accurately identify dominant sources of IL-17A in this
disease.
The findings of the present study demonstrate that IL-17A is
required for the accumulation of airwaymacrophages in response
to CS exposure, as assessed by use of a genetic KO mouse model
and a neutralizing Ab to IL-17A. Furthermore, innate sources
(macrophages, neutrophils and NK cells) of this pivotal cytokine
can compensate for the loss of functional T-cells in CS-challenge
models. Since macrophages are characterized as steroid-resistant
immune cells in COPD, their ability to express IL-17A may sus-
tain inflammation in a steroid-refractory manner. Macrophages
in particular, can orchestrate inflammatory responses in COPD
that can lead to deleterious remodelling of the airways. Airway
macrophages accumulate with progression of COPD [48] and
the selective depletion of macrophages in a chronic CS-exposure
model using clodronate prevented pulmonary emphysema [49].
The sustained accumulation of airway macrophages in COPD is
thought to be mediated by the production of chemokines that mo-
bilize monocytes from circulation into the inflamed lungs. In the
present study, both CCL2 and CCL3 were elevated in response
to CS exposure, which is consistent with this concept.
Since macrophage polarization phenotypes can be highly
plastic in response to external signals, the diversity of host,
environmental and microbial mediators within the COPD lung
microenvironment can dramatically influence the phenotype of
airway macrophages. Altered macrophage phenotypes are found
in COPD airways and are likely to contribute to deleterious in-
flammation and remodelling. MMP-12 has been identified as
one of the most highly induced genes in airway macrophages of
chronic smokers and represents a robust marker of an alternat-
ive activation state in both humans and mice [50]. In the present
study, both genetic ablation and Ab-based neutralization of IL-
17A potently suppressed MMP-12 expression in response to CS
exposure, implicating IL-17A in CS-mediated macrophage po-
larization.
In summary, the findings of the present study identify IL-17A
as an alternative target to combat macrophage accumulation in
CS-related lung conditions, in addition to reducing neutrophilic
inflammation. Importantly, we demonstrate that suppression of
T-cell function does not effectively reduce IL-17A-mediated in-
flammatory responses to CS exposure. Alternative innate cellular
sources should be considered when developing strategies to com-
bat excessive IL-17A signalling in chronic lung conditions.
CLINICAL PERSPECTIVES
• Cigarette smoke (CS) is the major cause of COPD. IL-17A is
a pivotal cytokine that regulates lung immunity and inflam-
mation. The aim of the present study was to investigate how
IL-17A regulates CS-induced lung inflammation in vivo.
• The results of the present study show that activation of in-
nate cellular sources of IL-17A is an essential mediator of
macrophage accumulation in CS-induced lung inflammation.
• These findings suggest that targeting non-T cell sources of
IL-17A may be an alternative strategy to reduce pathogenic
macrophages in COPD.
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